Moreover, because this interaction is unlikely to occur in healthy glial cells due to the low expression of Spastin and Pin1 [14], targeting this interaction may only influence cancer cells; hence, targeting this interaction may be a safe alternative for improving glioblastoma therapy. The gene discussed is SPAST; the disease is glioblastoma.